LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
STANDARD BIOTOOLS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.64+0.01 (+2.27%)
Close on Oct 19, 2026
- Market cap
- $251.45M
- P/E (TTM)
- 2.9
- Dividend yield
- –
STANDARD BIOTOOLS INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteomics | – | – | – | – | – | – | $135.79M | $115.54M | $94.98M | $84.86M | $63.88M | $61.03M | – | – |
| Genomics | – | – | – | – | – | – | $38.64M | $40.36M | $41.32M | $41.90M | $42.46M | $44.14M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteomics | – | – | – | – | – | – | -$61.90M | -$53.60M | -$50.49M | -$30.46M | -$21.41M | -$21.15M | – |
| Genomics | – | – | – | – | – | – | $3.20M | $2.53M | $910.00K | -$479.00K | -$106.00K | -$1.45M | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $61.17M | $62.33M | $61.66M | $62.70M | $64.68M | $64.90M | $65.43M | $76.65M | $79.58M | $85.35M | $79.20M | $78.73M | 72.3% | -5.4% |
| Consumables | $38.02M | $39.10M | $36.25M | $38.07M | $39.88M | $38.26M | $40.54M | $47.10M | $46.30M | $47.53M | $41.74M | $44.61M | 44.9% | -4.6% |
| Services and other revenue | $23.42M | $23.92M | $23.67M | $23.62M | $24.17M | $24.68M | $25.58M | – | – | – | $27.14M | – | 27.7% | -3.1% |
| Services and other revenue | $23.42M | $23.92M | $23.67M | $23.62M | $24.17M | $24.68M | $25.58M | – | – | – | – | – | 27.7% | -3.1% |
| Instruments | $23.15M | $23.24M | $25.41M | $24.62M | $24.80M | $26.63M | $24.89M | $29.55M | $33.28M | $37.82M | $37.46M | $34.12M | 27.4% | -6.7% |
| Service revenue | – | – | – | – | – | $77.71M | $81.13M | $66.23M | $48.36M | $40.13M | $25.98M | $25.17M | – | – |
| Product and service revenue | – | – | – | – | – | $164.92M | $169.70M | $152.96M | $134.21M | $125.48M | $105.18M | $103.91M | – | – |
| Other revenue | – | – | – | – | – | – | – | – | – | – | $1.16M | $1.27M | – | – |
| Collaboration and other revenue | – | – | – | – | – | $4.77M | $4.73M | $2.94M | $2.09M | $1.28M | $1.16M | – | – | – |
| Instrument support services | – | – | – | – | – | $23.98M | $24.65M | $25.30M | $25.56M | $25.01M | $25.27M | – | – | – |
| Assay services | – | – | – | – | – | $53.74M | $56.48M | $40.93M | $22.80M | $15.12M | $706.00K | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMEA | $35.95M | $36.45M | $35.99M | $34.71M | $36.34M | $36.29M | $35.65M | $39.23M | $38.51M | $40.88M | $36.20M | $38.22M | 42.5% | -1.1% |
| Americas | $30.20M | $31.24M | $30.56M | $33.63M | $35.55M | $36.03M | $37.40M | $56.81M | $57.92M | $59.20M | $46.20M | $43.48M | 35.7% | -15.0% |
| Asia-Pacific | $18.45M | $18.56M | $18.78M | $17.97M | $16.96M | $17.27M | $17.96M | $22.27M | $25.16M | $26.68M | $23.94M | $23.48M | 21.8% | +8.8% |
From the segment and revenue-disaggregation notes of Standard Biotools's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.